Skip to content
a16za16z

Taking Bold Bets: NIH and the Future of Biomedical Science

Dr. Jay Bhattacharya is one of the country’s top medical experts and a 24-year professor of medicine at Stanford. After being censored and deplatformed during COVID for his role in opposing harsh lockdowns, he was appointed Director of the National Institutes of Health by President Trump in 2025. a16z General Partners Erik Torenberg, Vineeta Agarwala, and Jorge Conde join Dr. Bhattacharya to discuss the administration’s role in tackling the autism crisis, how to restore public trust in health authorities, how to make the NIH more dynamic and efficient, and how to streamline publishing and restore academic freedom. Timecodes: 00:00 Introduction 00:59 Autism Research Initiatives Announced 02:01 New Findings: Leucovorin and Tylenol in Pregnancy 04:40 Addressing Preterm Birth & Broader Health Concerns 06:10 The Replication Crisis in Science 09:26 NIH Funding, Grant Review, and the Silicon Valley Spirit 12:47 Grant and Review Process 14:26 Portfolio Management & Allocation at NIH 26:23 The Challenge of Supporting Early Career Investigators 31:23 Allocating Grants and Training Under the New Administration 35:46 Academic Freedom and Scientific Publishing 38:34 Rebuilding Public Trust in Science & Public Health 41:57 Communicating Uncertainty & Scientific Honesty 48:58 NIH Priorities: Nutrition, Chronic Disease, and AI 54:15 Advice for the Next Generation of Scientists 56:37 The Role and Limits of AI in Science Resources: Find Dr. Bhattacharya on X: https://x.com/DrJBhattacharya and https://x.com/NIHDirector_Jay Find Erik on X: https://x.com/eriktorenberg Find Jorge on X: https://x.com/JorgeCondeBio Find Vineeta on X: https://x.com/vintweeta Learn more about the NIH: https://www.nih.gov/ Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X: https://x.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Listen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX Listen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711 Follow our host: https://x.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

Dr. Jay BhattacharyaguestErik TorenberghostVineeta AgarwalahostJorge Condehost
Sep 23, 202558mWatch on YouTube ↗

CHAPTERS

  1. Why public trust depends on evidence, transparency, and productive failure

    Bhattacharya opens with a thesis about rebuilding trust: treat the public as intelligent partners, show the data, and allow disagreement. He argues science should adopt a “Silicon Valley spirit” that rewards learning—including learning from failure—rather than punishing it.

  2. Autism Data Science Initiative: $50M, 13 teams, and a push for causes & prevention

    He announces a new NIH autism effort prompted by rising prevalence and lack of clear answers for families. The initiative funds large, data-science-oriented projects intended to accelerate understanding of causes and potential prevention strategies.

  3. Clinical signals in focus: leucovorin for subsets of autism and caution on Tylenol in pregnancy

    Two additional announcements highlight translation to care: expanding access to leucovorin (folinic acid) for specific folate-processing issues, and updated caution/guidance around acetaminophen use during pregnancy. He emphasizes nuance—potential benefits for some, uncertainty for others—and avoiding panic while acting prudently.

  4. Preterm birth as a national outcomes gap and a family-centered research mandate

    The conversation expands to preterm birth, noting the U.S. has worse outcomes than parts of Europe and lacks sufficient explanations. Bhattacharya frames NIH’s role as delivering rigorous science that responds to real family concerns, while acknowledging complexity and multiple contributing factors.

  5. The replication crisis: why “published” doesn’t mean “true”

    Bhattacharya diagnoses replication as the core standard for scientific truth and argues current incentives undervalue verification. He attributes the crisis to the difficulty and scale of modern science, specialization, and weak incentives to check others’ work or publish negative/failed replications.

  6. NIH reform agenda: auditability, centralized review, and modernizing collaboration oversight

    Reflecting on his first months, he highlights operational reforms: strengthening accountability for foreign collaborations and centralizing grant review processes. He argues these changes preserve global collaboration while ensuring the U.S. can track funds and verify compliance.

  7. Bringing venture-style portfolio thinking to NIH: bold bets, tolerance for failure, and newer ideas

    He draws a direct analogy to venture capital portfolios: many failures can be acceptable if the portfolio produces transformative wins. He argues NIH became more conservative over time—funding older, safer ideas—and needs to renew incentives for experimentation and learning.

  8. Allocation vs execution: who decides priorities, and why politics can’t be removed

    Agarwala frames NIH’s challenge as both allocating dollars across areas and executing well within each area; Bhattacharya agrees and explains why public (political) input is appropriate for macro allocation. He argues scientists are essential within-area decision makers, but not legitimate “philosopher kings” for societal tradeoffs.

  9. Early-career investigator bottleneck: aging of first grants, postdoc inflation, and new incentives

    Bhattacharya describes how the system increasingly delays independence for young scientists, shifting first major grants from mid-30s to mid-40s and encouraging multiple postdocs. He proposes changes that judge institutes on portfolio outcomes, strengthen alignment to strategic plans, and reward mentorship and early-career support.

  10. Training and the “missing link”: bridging from training grants to faculty independence

    The discussion turns to NIH training mechanisms (pre-doc, postdoc, MSTP) and where attrition occurs. Bhattacharya argues the biggest failure point is the transition from training to independent positions and that NIH should reward institutions and structures that make that leap feasible.

  11. Rebuilding public health trust after the pandemic: gold-standard science and humility

    Bhattacharya links today’s trust deficit directly to pandemic-era policies he views as weakly evidenced and harmful. He proposes two pillars for repair: enforce “gold-standard science” norms (replication, unbiased review, humility) and reframe public health as servant-partner to the public rather than a commanding authority.

  12. Communicating uncertainty: say ‘I don’t know,’ avoid false certainty, and invite open debate

    He argues that in uncertain situations, honesty about unknowns is essential and that overconfident guidance erodes credibility. At the same time, he distinguishes between areas of genuine uncertainty and areas with strong evidence (e.g., MMR), advocating open scientific discourse rather than censorship or “canceling.”

  13. NIH priorities: chronic disease, nutrition, and AI—plus practical examples like Alzheimer’s prevention signals

    Bhattacharya outlines priorities including chronic disease burden and integrating AI, emphasizing translational opportunities. He highlights observational findings suggesting an old shingles vaccine (Zostavax) may reduce Alzheimer’s cognitive decline risk, illustrating the kind of pragmatic, high-upside hypothesis he wants to pursue.

  14. The role and limits of AI: augmentation over substitution, plus guarding against system noise

    AI’s promise includes protein-structure tools (e.g., AlphaFold), radiology assistance, and reducing clinician documentation burden. But Bhattacharya warns of hallucinations, low-quality AI-generated grant spam, and the need for policies that keep AI from overwhelming review systems while enabling secure internal use.

  15. Advice to scientists: persist like Max Perutz—and why portfolios must allow long, uncertain bets

    Closing advice centers on resilience and conviction: transformative discoveries often require years of persistence despite skepticism. He uses Max Perutz’s decade-long pursuit of protein structure to argue NIH must create conditions where such long-horizon, high-risk work can survive and succeed.

Get more out of YouTube videos.

High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.

Add to Chrome